Roman M Chicz

US Patent:

6509033, Jan 21, 2003

Filed:

Jun 7, 1995

Appl. No.:

08/475399

Inventors:

Robert Glen Urban - Cambridge MA
Roman M. Chicz - Jamaica Plain MA
Dario A. A. Vignali - Rainham, GB
Mary Lynne Hedley - Somerville MA
Lawrence J. Stern - Arlington MA
Jack L. Strominger - Lexington MA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 9127

US Classification:

424450, 514 44, 536 231, 536 232, 536 235, 536 2351, 536 237, 536 2352, 536 2353, 536 234, 536 2372, 4353201

Abstract:

A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.

US Patent:

6562943, May 13, 2003

Filed:

Apr 20, 2000

Appl. No.:

09/552802

Inventors:

Mark Peakman - London, GB
Roman M. Chicz - Belmont MA

Assignee:

Zycos, Inc. - Cambridge MA
Kings College London - London

International Classification:

A61K 3804

US Classification:

530324

Abstract:

The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e. g. , autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.

US Patent:

6582704, Jun 24, 2003

Filed:

Jan 12, 2001

Appl. No.:

09/759960

Inventors:

Robert G. Urban - Lexington MA
Roman M. Chicz - Belmont MA
Edward J. Collins - Carrboro NC
Mary Lynne Hedley - Lexington MA

Assignee:

Zycos Inc. - Lexington MA

International Classification:

A61K 3912

US Classification:

4242041, 4241861, 4241851, 435 691, 435 697, 536 2372, 530300, 530350

Abstract:

The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.

US Patent:

6696061, Feb 24, 2004

Filed:

Jun 15, 1993

Appl. No.:

08/077255

Inventors:

Robert Glen Urban - Lexington MA
Roman M. Chicz - Belmont MA
Dario A. A. Vignali - Rainham, GB
Mary Lynne Hedley - Lexington MA
Lawrence J. Stern - Arlington MA
Jack L. Strominger - Lexington MA

Assignee:

President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 3817

US Classification:

4241851, 4242771, 4242781, 424810, 424450, 4242831, 514 2, 514885, 514 15, 514 14, 514 13, 514 12, 530806, 530328, 530327, 530326, 530325, 530324

Abstract:

A purified preparation of a peptide consisting essentially of an amino acid sequence identical to that of a segment of a naturally-occurring human protein, said segment being of 10 to 30 residues in length, inclusive, wherein said peptide binds to a human major histocompatibility complex (MHC) class II allotype.

US Patent:

7097843, Aug 29, 2006

Filed:

Jun 24, 2003

Appl. No.:

10/603062

Inventors:

Robert G. Urban - Lexington MA, US
Roman M. Chicz - Belmont MA, US
Edward J. Collins - Carrboro NC, US
Mary Lynne Hedley - Lexington MA, US

Assignee:

MGI Pharma Biologics, Inc. - Lexington MA

International Classification:

A61K 39/12

US Classification:

4242041, 4241861, 530300

Abstract:

The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.

US Patent:

7173108, Feb 6, 2007

Filed:

Mar 3, 2003

Appl. No.:

10/378479

Inventors:

Mark Peakman - London, GB
Roman M. Chicz - Belmont MA, US

Assignee:

MGI Pharma Biologics, Inc. - Lexington MA
King's College London - London

International Classification:

C07K 7/00
C07K 14/00

US Classification:

530324, 530325, 530326, 530327, 530806, 530868

Abstract:

The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e. g. , autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.

US Patent:

7408029, Aug 5, 2008

Filed:

Feb 2, 2007

Appl. No.:

11/670818

Inventors:

Mark Peakman - London, GB
Roman M. Chicz - Belmont MA, US

Assignee:

MGI PHARMA Biologics, Inc. - Lexington MA
King's College London - London

International Classification:

C07K 14/00
C07K 4/12

US Classification:

530328, 530324, 530325, 530326, 530327

Abstract:

The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e. g. , autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.

US Patent:

7408031, Aug 5, 2008

Filed:

Feb 2, 2007

Appl. No.:

11/670830

Inventors:

Mark Peakman - London, GB
Roman M. Chicz - Belmont MA, US

Assignee:

MGI PHARMA Biologics, Inc. - Lexington MA
King's College London - London

International Classification:

C07K 4/12
C07K 14/00

US Classification:

530329, 530324, 530325, 530326, 530327, 530328

Abstract:

The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e. g. , autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.